AP NEWS

Global Anthrax Treatment Market 2019-2023 | Novel Therapies for the Treatment of Anthrax to Boost Demand | Technavio

November 26, 2018

LONDON--(BUSINESS WIRE)--Nov 26, 2018-- analysts forecast the global anthrax treatment market to grow at a CAGR of over 8 % during the forecast period, according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181126005514/en/

Technavio analysts forecast the global anthrax treatment market to grow at a CAGR of over 8% by 2023. (Graphic: Business Wire)

Increase in research funding is one of the major trends being witnessed in the . There has been a rise in research funding for the development of therapies for the treatment of anthrax. The funding will allow additional anthrax vaccine characterization and inspection of mucosal immune response. The rapid diagnosis of anthrax infections will allow for more effective treatment.

This report is available at a USD 1,000 discount for a limited time only:

According to Technavio analysts, one of the key factors contributing to the growth of the global anthrax treatment market is the novel therapies for the treatment of anthrax:

Global anthrax treatment market: Novel therapies for the treatment of anthrax

There has been an increase in the development of novel therapies for anthrax due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. Although clinical trials have been conducted to examine the safety and pharmacodynamics in humans, efficacy studies are inadequate. Also, novel antimicrobial strategies are in development to replace the antibiotics against anthrax bacilli.

According to a senior analyst at Technavio, “New approaches have been identified for the treatment of systemic anthrax such as the use of toxin-neutralizing antibodies used in conjugation with antimicrobial agents. Also, anthrax immune globulin, a polyclonal preparation of antibodies derived from a pooled plasma of healthy anthrax-vaccinated donors, has been used in the management of some cases of anthrax as well.”

Global anthrax treatment market: Segmentation analysis

The global anthrax treatment market research report provides market segmentation by product (vaccine and drug therapy) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The Americas held the largest share of the market in 2018, accounting for close to 89% share. It was followed by EMEA and APAC respectively. Factors such as initiatives by organizations like the CDC supporting the development of novel therapies for the treatment of anthrax drives market growth in the Americas.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181126005514/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 11/26/2018 10:36 AM/DISC: 11/26/2018 10:36 AM

http://www.businesswire.com/news/home/20181126005514/en

AP RADIO
Update hourly